U.S. markets open in 3 hours 52 minutes

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7856-0.0144 (-1.80%)
At close: 04:00PM EDT
0.7975 +0.01 (+1.51%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.8000
Bid0.0000 x 800
Ask0.0000 x 1100
Day's Range0.7652 - 0.8099
52 Week Range0.6800 - 2.6500
Avg. Volume547,604
Market Cap177.681M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.5200
Earnings DateAug 09, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ADAP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adaptimmune Therapeutics plc
    XNCR: Lowering target price to $21.00XENCOR INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Newsfile

    Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Development. Dr. Chagin will oversee the Company's early-stage pipeline activities from pre-IND and IND activities through Phase 1 clinical trials. Karen joins Adaptimmune from Tmunity where she served as Chief Me

  • Newsfile

    Adaptimmune Reports Second Quarter Financial Results and Business Update

    Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023Transition of lete-cel from GSK and data from the completed pivotal trial in synovial sarcoma and MRCLS expected in late 2023Initiated Phase 2 SURPASS-3 trial in ovarian cancer, which has the potential to be registrational and is supported by RMAT designation Completed strategic combination with TCR2 ...

  • Newsfile

    Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023

    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US markets open on Wednesday, August 9, 2023. Following the announcement, the Company will host a live conference call at 8:00 a.m. EDT (1:00 p.m. BST) that same day.The press ...